EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Neuland Laboratories EBITDA Margin % Related Terms
Neuland Laboratories EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Neuland Laboratories's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Neuland Laboratories's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuland Laboratories EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neuland Laboratories's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Neuland Laboratories's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neuland Laboratories (NSE:NEULANDLAB) has a EBITDA Margin % of 41.20% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Neuland Laboratories and its competitors. This is 135% above median its historical median of 17.52. Over the past decade, Neuland Laboratories' EBITDA Margin % has ranged from 8.51 to 31.16. According to the industry distribution chart, Neuland Laboratories ranks #132 out of 955 companies in the Drug Manufacturers industry, placing it in the top 13.8%.
Is Neuland Laboratories' EBITDA Margin % too high?
Neuland Laboratories' current EBITDA Margin % of 41.20% is 135% above median its 10-year median of 17.52. Over the past 10 years, this metric has ranged from a low of 8.51 to a high of 31.16. The Drug Manufacturers industry median EBITDA Margin % is 12.39. Neuland Laboratories' value of 41.20% is 232.5% above this industry median. Based on the distribution chart, Neuland Laboratories ranks #132 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Neuland Laboratories has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Neuland Laboratories' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Neuland Laboratories ranks #132 out of 955 companies for EBITDA Margin %. This places Neuland Laboratories in the top 14% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.39. Neuland Laboratories' value of 41.20% is 232.5% above this benchmark. Historically, Neuland Laboratories' own EBITDA Margin % has ranged from 8.51 to 31.16 over the past decade. While the company's 10-year median is 17.52 vs. the industry median of 12.39, Neuland Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neuland Laboratories's current EBITDA Margin % of 41.20% is 232.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Neuland Laboratories and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neuland Laboratories's current EBITDA Margin % is 41.20%, which is 135% above median its own 10-year median of 17.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuland Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Neuland Laboratories (NSE:NEULANDLAB) is currently considered Fairly Valued. The stock's GF Value™ is ₹16,462.93, compared to a current price of ₹17,961.00 — trading 9.1% above its estimated fair value. The current EBITDA Margin % is 41.20%, which is 135% above median its 10-year median of 17.52 and 232.5% above the Drug Manufacturers industry median of 12.39. Neuland Laboratories' overall GF Score™ is 90/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Neuland Laboratories (NSE:NEULANDLAB), the current EBITDA Margin % is 41.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neuland Laboratories (NSE:NEULANDLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Neuland Laboratories stock appears to be overvalued.
The current stock price of ₹17,961.00 is trading 9.1% above its estimated GF Value™ of ₹16,462.93.
GuruFocus considers Neuland Laboratories to be Fairly Valued.
Key valuation signals for NSE:NEULANDLAB:
EBITDA Margin %: 41.20% (135% above median its 10-year median of 17.52)
GF Value™: ₹16,462.93 vs. price of ₹17,961.00 (9.1% above fair value)
Industry Position: 232.5% above the Drug Manufacturers median (#132 of 955)
No single metric tells the full story. See the NSE:NEULANDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neuland Laboratories Ltd is engaged in the manufacturing and selling of bulk drugs and caters to both the domestic and international markets. It is an API contract development and manufacturing organization (CDMO), supporting biotechnology and pharmaceutical companies in the design, development, and manufacturing of complex active pharmaceutical ingredients (APIs). The company develops small molecules and peptides for clinical trials and beyond, with the capacity to scale up through every stage of the product lifecycle to commercial manufacturing. Geographically, the group derives maximum revenue from its customers in India, followed by Europe, the USA and North America, and the Rest of the world.
90GF Score
Get the complete analysis for NSE:NEULANDLAB
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NEULANDLAB has been successfully added to your 
